- Open Access
Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients
© Turksma et al.; licensee BioMed Central Ltd. 2013
- Received: 22 February 2013
- Accepted: 10 June 2013
- Published: 20 June 2013
New treatment modalities are needed for the treatment of cancers of the head and neck region (HNSCC). Survivin is important for the survival and proliferation of tumor cells and may therefore provide a target for immunotherapy. Here we focused on the ex vivo presence and in vitro induction of survivin specific T cells.
Tetramer staining and ELIspot assays were used to document the presence of survivin specific T cells in patient derived material, and to monitor the presence and persistence of survivin specific T cells after repeated in vitro stimulation with autologous dendritic cells.
Ex vivo analysis showed the presence of survivin-specific T cells in the peripheral blood (by tetramer analysis) and in the draining lymph node (by ELIspot analysis) in a HNSCC and a locally advanced breast cancer patient respectively. However, we were unable to maintain isolated survivin specific T cells for prolonged periods of time. For the in vitro generation of survivin specific T cells, monocyte derived DC were electroporated with mRNA encoding full length survivin or a survivin mini-gene together with either IL21 or IL12 mRNA. Western blotting and immunohistochemical staining of dendritic cell cytospin preparations confirmed translation of the full length survivin protein. After repeated stimulation we observed an increase, followed by a decrease, of the number of survivin specific T cells. FACS sorted or limiting dilution cloned survivin specific T cells could not be maintained on feeder mix for prolonged periods of time. Protein expression analysis subsequently showed that activated, but not resting T cells contain survivin protein.
Here we have shown that survivin specific T cells can be detected ex vivo in patient derived material. Furthermore, survivin specific T cells can be induced in vitro using autologous dendritic cells with enforced expression of survivin and cytokines. However, we were unable to maintain enriched or cloned survivin specific T cells for prolonged periods of time. Endogenous expression of survivin in activated T cells and subsequent fratricide killing might explain our in vitro observations. We therefore conclude that survivin, although it is a universal tumor antigen, might not be the ideal target for immunotherapeutic strategies for the treatment of cancer of the head and neck.
- DC based vaccines
- Messenger RNA
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer in the world [1, 2]. In the past decades there has been little improvement in the survival rate of HNSCC patients, which is relatively low. Therefore, the development of novel therapies is important. An attractive therapeutic option is immunotherapy, which can be implemented after standard treatment like surgery, radiotherapy or chemotherapy [3–5].
Tumor specific T cells can recognize and kill tumor cells either directly or through the production of cytokines. Dendritic cells loaded with tumor antigens can stimulate T cells leading to T cell activation and expansion. Ideally, tumor associated antigens (TAA) are specific for tumor cells, however, most tumor antigens are also expressed in normal tissues albeit often at lower levels. In a number of cases tumor antigens are derived from proteins that promote transformation and tumor genesis and may even be required to maintain a malignant phenotype .
Examples of well-known tumor antigens expressed in HNSCC are p53, Mage-A3, Her2/neu and survivin [7–10]. Survivin is an inhibitor of apoptosis and involved in mitotic spindle formation [11, 12]. Survivin is highly expressed in most cancers, but only to a small extent in normal tissue . In normal cells it is expressed in a cell-cycle dependent matter, i.e. only during mitosis, after which it is rapidly degraded . Survivin is a protein that is important for the tumor’s survival and proliferation, and therefore an interesting TAA candidate. Survivin expression in malignant tumors has been associated with poor prognosis .
Five splice variants of survivin have been identified: full length or wild type (wt) survivin, survivin 2B, 3B, Dex3 and 2alpha. Survivin wt, 2B and 3B are expressed in the cytoplasm, Dex3 in the nucleus and 2A in the cytoplasm and nucleus. Like survivin wild type, the splice variant Dex3 appears to be anti-apoptotic , whereas survivin 2A and 2B may be pro-apoptotic [17–19]. In oropharyngeal tumors and upper urinary tract urothelial carcinoma, nuclear expression of survivin is associated with a poor prognosis [20, 21].
In healthy donors survivin specific T cell frequencies in the peripheral blood are often very low, if not undetectable . In cancer patients somewhat higher percentages of survivin specific T cells can be detected in peripheral blood . Survivin specific T cells have been found in several types of tumors, like breast cancer, leukemia, colorectal cancer and melanoma patients [23–28]. According to Weide et al. the absence of survivin specific T cell reactivity in the blood of patients with distant melanoma metastasis is a poor predictor of overall survival, whereas the presence of NY-ESO and Mage-3 specific T cells is a good predictor .
In murine models survivin vaccination has been shown to eradicate tumors by inducing survivin specific CD8+ T cells [30–33]. Zeis et al. demonstrated that by using survivin mRNA transfected dendritic cells (DC) to vaccinate mice, long term resistance to lymphoma challenge was obtained. Subsequently they showed that survivin specific T cells were capable of killing tumor cell lines , indicating that survivin is immunogenic and could be a useful target for immunotherapeutic strategies.
Moderate results have been reported in phase I/II trials where cancer patients have been vaccinated with synthetic survivin peptides [34–37]. In a phase I trial, myeloma patients received autografts followed by ex vivo anti-CD3/anti-CD28 co-stimulated autologous T cells at day 2 after transplantation. Half of the patients additionally received hTERT and survivin peptide immunizations resulting in increased survival compared to the group that did not receive additional vaccination . Unfortunately no distinction was made in the tetramer readout system between survivin and hTERT, therefore the role of survivin in the patients immune response remains unclear. Data obtained from a phase-II peptide vaccination trial in metastatic melanoma showed that survivin-specific T reactivity in about one fifth of the patients correlated with increased overall survival . In a phase I trial the splice variant survivin 2B peptide has been used in HLA-A24 positive patients with oral cancer. Although the response rate was low (one partial responder and nine patients with progressive disease), an increase in survivin specific T cells was observed after vaccination .
Here we document the presence of survivin specific T cells in patient derived peripheral blood and lymph nodes and report on our efforts to induce and maintain survivin specific T cells, employing CD8+ T cells and autologous dendritic cells transfected with mRNA encoding survivin in combination with interleukin 12 or interleukin 21.
Peripheral blood from five HLA-A2 positive HNSCC patients was used to monitor the presence of survivin specific T cells. The HNSCC patients were treated at the VU University Medical Center in Amsterdam, the Netherlands with surgery, chemotherapy, radiotherapy or a combination of these. Blood was drawn at least six weeks after the last treatment via a vena puncture. All patients signed an informed consent form, approved by the Institutional Review Board (METc-VUmc registrationnumber:2009/205). Lymph node derived T cells from a patient suffering from locally advanced breast cancer was used to determine TAA specific T cells by ELIspot. The patient took part in a IRB-approved clinical trial where she received 6 neoadjuvant chemotherapy cycles and signed a written informed consent (METc-VUmc IRB00002991 IORG number 0002436).
DNA vectors and in vitro transcription of mRNA
Multiple survivin constructs were designed, the survivin inserts were codon modified and generated by Geneart (Regensburg, Germany) and cloned into pGEM4Z vectors (kindly provided by dr. Viggo van Tendeloo, Antwerp, Belgium). The mini-survivin sequence (including the immunodominant HLA-A2 binding T cell epitope) was cloned into pGEM as an EcoRI-NotI fragment, resulting in pGEM-mini-survivin (mini-survivin in short for the mRNA). The resulting open reading frame encoded the following amino-acid-sequence; MQFTELTLGEFLKL DREEEREAEFKSAFTELTLGEFLKL DREEREEERRNKQFTELTLGEFLKL DREEREEERR FNKKQFTELTLGEFLKL DRE*.
The Ubi-mini-survivin sequence was cloned into pGEM as an XhoI-NotI fragment, resulting in pGEM-Ubi-mini-survivin (Ubi-mini-survivin in short for the mRNA). The open reading frame encoded the following amino-acid-sequence; MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGVVN SEKFQFTELTLGEFLKL DREEEREAEFKSAFTELTLGEFLKL DREEREEERRNKQFTELTLGEFLKL DREEREEERR FNKKQFTELTLGEFLKL DRE*.
The immunodominant HLA-A2 binding T cell epitope survivin(96–104) is indicated in bold in both sequences. The survivin(96–104 epitope is located in the 3rd exon of survivin and is therefore present in wild type survivin and the splice variants 2B and 3B, but absent in survivin splice variants 2alpha and Dex3.
Two full length survivin wild type constructs were used (pGEM-survivin and pGEM-Ubi-survivin along the lines described above. A codon-modified minigene (Ubi-mini-MART for the mRNA) containing four repeats of the altered peptide ligand ELAGIGILTV (was used as described before ). In vitro transcription was carried out according to manufacturer’s protocol of the T7 mMessage-mMachine kit (Ambion, Huntingdon, Cambridgeshire, UK) to generate m7G(50)pppGcapped IVT mRNA (CAP). mRNA quality was checked by agarose gel electrophoresis. RNA concentration was assayed by spectrophotometrical analysis at OD260.
Dendritic cell generation and phenotype analysis
Healthy donor derived peripheral blood mononuclear cells (PBMC) were isolated from HLA-A2 positive buffycoats (Sanquin, Amsterdam, The Netherlands) by density gradient centrifugation using Lymphoprep (Nycomed, Oslo, Norway). Monocytes were isolated by positive selection using a MACS column (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany). PBMCs were labeled with anti-CD14 beads (Miltenyi Biotec) followed by MACS sorting according to the manufacturer’s protocols. Subsequently, the monocytes were cultured with 100 ng/mL recombinant human granulocyte colony stimulating factor (rhGM-CSF; Sagramostim, Berlex) and 10 ng/mL interleukin 4 (IL4; R&D systems) for 6 to 7 days in IMDM medium supplemented with 8% fetal calf serum (FCS; HyClone), 2 mM L-glutamine and antibiotics (100 IE/ml penicillin and 100 μg/mL streptomycin, life technologies). The immature DCs were then matured by culturing them with monocyte conditioned medium (MCM) 25% v/v (generated as previously described ) and 50 ng/mL tumor necrosis factor (TNF)α (Miltenyi Biotec). DCs were analyzed phenotypically to determine the maturation status using flow cytometry. The following antibodies were used for phenotypic analysis: IgG1, CD14, CD80, CD83, HLA-DR (BD Biosciences, Heidelberg, Germany), CD1a, CD86, CD40 (Pharmingen, San Diego, CA, USA) labeled with Phycoerythrin (PE). Mean fluorescence index was calculated as follows: MFI-Index = (mean fluorescence intensity marker)/(fluorescence intensity isotype).
Preparation of dendritic cells for the detection of survivin in western blot and cytospins
Mature DC were electroporated  with eGFP, Ubi-survivin or survivin mRNA. Cells were electroporated with 10 μg mRNA in 200 μL electrobuffer (Cell Projects Ltd) in 4 mm cuvets (Cell Projects Ltd) at 300 Volt and 150 μF (Easyject plus, Equibio, Kent, UK). One hour after electroporation cells were washed and plated out in 1*106/mL IMDM medium supplemented with 8% fetal calf serum (FCS; HyClone), 2 mM L-glutamine and antibiotics (100 IE/ml penicillin and 100 μg/mL streptomycin, life technologies).
For Western blot, 4 hours after electroporation with mRNA encoding either eGFP, survivin or Ubi-survivin 1*106 cells were harvested and washed with phosphate-buffered saline (PBS). DC were harvested for cytospin preparations, at time points 2, 4, 6, and 24 hours after electroporation with RNA encoding either eGFP, survivin or Ubi-survivin.
T cell activation and survivin protein detection
Isolation of resting CD8β positive T cells from HLA-A2 positive, healthy donor PBMC (Sanquin) was performed by positive selection using a MACS column (Miltenyi Biotec). For this purpose, total PBL were incubated with anti-CD8β mAb (clone: 2ST8.5H7, Beckman Coulter, Inc.) and subsequently with microbead-conjugated anti-mouse IgG Abs (Miltenyi Biotec), followed by MACS sorting according to the manufacturer’s protocol. Per donor 6*106 CD8β + T cells were cultured in Yssels medium supplemented with 1% hAB in order to obtain resting T cells. Another aliquot of CD8β + T cells were cultured in the presence of 100 U/mL IL2 and 500 ng/mL PHA in order to obtain activated T cells. After a 48 hour incubation period, the T cells were harvested for FACS and Western blot analysis. T cell activation levels were determined by incubating the T cells with anti-CD25 PE and CD69 FITc (BD Biosciences). Cells were subsequently measured by flow cytometry.
Western blot analysis
Cell pellets were resuspended in lysis buffer (50 mmol/l Tris/HCl, pH 8.0, 0.5% NP-40, 5 mmol/l EDTA) containing protease inhibitors. Protein levels in the samples were quantified according to manufacturer’s protocol using BCA Protein Assay Kit (Pierce Biotechnology, Rockford, USA). Expression of survivin was detected using a 1:1000 dilution of rabbit-anti-survivin (clone 71G4B7, Cell Signaling Technology, Inc, Boston, USA), followed by incubation with a 1:1000 dilution of polyclonal swine-anti-rabbit immunoglobulin/HRP (DakoCytomation, Glostrup, Denmark). Proteins were visualized with the enhanced chemo-luminescence technique (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
Cytospin samples of dendritic cells were prepared as followed; per condition 20.000 cells were taken up in 100 uL PBS and spun down for 3 minutes at 600 rpm on a Superfrost plus slide (Thermo Scientific, Braunschweig, Germany). Cytospins were next air dried overnight, fixed in acetone for 10 minutes and stained with anti-survivin(clone 71G4B7, Cell Signalling Technology, Inc.). According to the manufacturer this rabbit mAb was produced by immunizing animals with a synthetic peptide corresponding to residues surrounding cysteine 60 of human survivin and detects endogenous levels of total survivin protein.
Induction of survivin specific CD8+ T cells and detection by tetramer binding
Isolation of resting CD8β positive T cells from healthy donor PBMC (Sanquin) was performed by positive selection using a MACS column (Miltenyi Biotec). For this purpose, total PBL were incubated with anti-CD8β mAb (clone: 2ST8.5H7, Beckman Coulter, Inc., Marseille, France) and subsequently with microbead-conjugated anti-mouse IgG Abs (Miltenyi Biotec), followed by MACS sorting according to the manufacturer’s protocol. Mature DC were electroporated with survivin mRNA in combination with IL12 mRNA or IL21 mRNA as described above. One hour after electroporation DCs were washed and multiple mini-cultures containing 0.5–1 ×106 CD8β T cells, 0.5–1 ×105 mRNA-transfected DCs and 0.25–0.5 ×106 irradiated autologous CD4+ T cells were set up in Yssel’s medium supplemented with 1% hAB and 10 U/mL IL7. After 10 days, T cells were analyzed for specificity using PE- and/or APC-labeled HLA-A*0201 tetramers (Tm) presenting the survivin 5, 95, 96 or 96 M epitope (survivin 5–14: TLPPAWQPF, survivin 95–104: ELTLGEFLKL, survivin 96–104: LTLGEFLKL, survivin 96 M: LM LGEFLKL). We have used in-house prepared tetramers, which at that moment in time could not be tested for specific binding since bona fide survivin specific T cell clones were unavailable to us. In a similar case in the past we have validated HPV specific tetramers by using two different fluorescent dyes , thus excluding non-specific binding of one of the tetramers. Staining was performed in PBS supplemented with 0.1% BSA and 0.01% Sodium azide for 15 min at 37°C. On day 10 the bulk cultures were re-stimulated with mRNA electroporated DCs and the next day 20 U/mL IL2 (R&D systems, Oxon, UK) was added. Tetramer staining was performed after 7 days and the bulk cultures were re-stimulated weekly as described above.
ELIspot assay to measure cellular production of IFN- γ
Tumor-draining lymph node material, from patients suffering from locally advanced breast cancer, was used to determine the presence of survivin specific T cells. Antigen-induced interferon gamma (IFN-γ) secretion by survivin induced T cells was measured by an EnzymeLinked Immuno-spot (ELIspot) assay using a modification of a described technique . After wells of nitrocellulose-bottom 96-well plates (MultiScreen-HA; Millipore, Billerica, MA) were coated overnight with 50 μL monoclonal anti-IFN-γ antibody (10 μg/mL; R&D Systems, Minneapolis, MN), the plates were washed, 1% bovine serum albumin was added to each well to block nonspecific binding, and the plates were washed again. The survivin long peptides shown in Additional file 1: Figure S1C were used to load target cells (autologous moDCs). DCs alone or with the survivin long peptides (5 μM) were added in a total volume of 100 μL of complete RPMI medium to the wells and incubated at room temperature for 1 h. The CD4+ or CD8+ T cells were added (1 × 104 cells/well) in 100 μL of complete RPMI medium with added IL2 (20 U/mL) and incubated for 48 h at 37°C with the target cells (1 × 103 cells per well). After the plates were washed, captured IFN-γ was detected by incubation with 50 μL of biotin-conjugated goat anti-human IFN-γ (R&D systems) for 2 h at 37°C in the dark, and the plates were rewashed, incubated for 1 h at 37°C with streptavidin-alkaline phosphatase (Zymed, San Francisco, CA) diluted 1:10.000 in conjugate buffer (1% bovine serum albumin in PBS plus 0.05% Tween 20), washed, and incubated with 50 μL of FAST 5-bromo-4-chloro-3-indolylphosphate nitroblue tetrazolium (BCIP/NBT) substrate (Sigma) for 30 min at 37°C in the dark. After drying the plates overnight in the dark, spot-forming cells (SFC) corresponding to individual IFN-γ-secreting cells were counted using an AID ELISPOT reader (Autoimmun Diagnostika GmbH, Strasbourg, Germany). The background number of SFC was determined by incubating the CD8+ cells with autologous moDCs alone or autologous moDCs loaded with irrelevant peptide (HPV long peptide), and wells containing CD8+ T cells were included as a negative control. Each determination was performed in duplicate, and the results were expressed as SFC/number of plated CD8+ T cells.
Survivin specific CD8 positive T cells in peripheral blood and lymph nodes from cancer patients
In a tumor-draining lymph node obtained from another patient, in this case suffering from locally advanced breast cancer and treated with six cycles of neo-adjuvant chemotherapy, we detected tumor antigen associated specific T cells. The spontaneously arising T cells were tested in an interferon-gamma ELIspot assay against a number of different nine-mer HLA-A2-binding peptides representing tumor associated CTL epitopes; Survivin-95, CEA-571, Her-2/Neu-369 and Her-2/Neu-654. As a negative control we used the virally derived HPV16E7(11–20) peptide. Indicated are the number of spots per 100.000 T cells. The results given in Figure 1C clearly shows survivin specific reactivity amongst reactivity against other TAA.
Having established that spontaneously arising survivin specific T cells can be detected in cancer patients we embarked on in vitro induction experiments using healthy donor derived mature DC, electroporated with in vitro transcribed mRNA, as stimulator cells and isolated CD8+ T cells as responders, the purpose being to optimize T cell stimulation protocols, employing mature DC, survivin and cytokine encoding mRNA, for in vivo vaccination studies in HNSCC cancer patients.
DNA constructs encoding survivin
Detection of survivin protein in transfected cells
Next we determined survivin expression in mature DC by immunohistochemical staining of cytospin preparations (Figure 3B). Cytospins were prepared at 2, 4, 6, 8 and 24 hours after electroporation of mature DC. Low level survivin staining was seen in GFP and in Ubi-survivin electroporated DC at all time points included in the analysis. Staining of survivin protein was most prominent in cytospins taken at 4 h and 6 h after electroporation of mature DC with full length survivin encoding mRNA. Specific staining was reduced to background level in these cells taken at time point 24 h. From these experiments we concluded that the full length survivin sequence, used in two of the DNA constructs shown in Figure 2, is capable of driving the production of survivin protein.
Induction of antigen specific CD8 positive T cells from healthy donors
Next to the induction of survivin specific T cells we applied our protocols to the induction of Influenza specific (memory) T cells using peptide loaded mature DC, and Mart-1 specific (naive) T cells using mRNA electroporated mature DC [38, 41]. CD8+ T cells and monocyte derived mature DC from an HLA-A2 positive healthy donor were used.
Next we stimulated T cells with mature DC co-electroporated with full length survivin mRNA and IL21 mRNA. After as many as five in vitro stimulations we detected low levels of survivin specific T cells staining with tetramers containing either the wild type (0.2% positive for survivin(96–104) or M-modified survivin(96–104) epitope (0.5% positive)). Results are shown in Figure 4B. We noted interferon-γ production as measured in an ELIspot assay upon incubation of T cells with peptide loaded DC for this donor but not for a second donor (see Additional file 1: Figure S1 and Additional file 2: Table S1). After limiting dilution cloning, outgrowth of T cells was found in 69 of 920 wells seeded with survivin tetramer binding T cells obtained after FACS sorting. None of these wells,however, contained viable survivin(96–104) specific T cells.
Survivin protein expression in activated T cells
In our efforts to improve treatment of patients with HNSCC we embarked on the induction of T cell responses against widely expressed tumor antigens. One such tumor antigen is survivin which is expressed in almost all tumor types, including HNSCC, and is essential for tumor cell survival. Our laboratories have a substantial track record with respect to the induction, isolation and maintenance of human T cells. In the past we have isolated T cells against a variety of tumor antigens, amongst which Human Papilloma Virus, Mart-1, human telomerase reverse transcriptase (hTERT), ErbB3-binding protein-1 (Ebp1), carcinoembryonic antigen (CEA) and Her-2/neu [41, 43–52].
Here we have shown the presence of survivin specific T cells in PBMC of an HNSCC patient by means of tetramer staining (Figure 1A; binding of survivin(5–14): TLPPAWQPF) and in the draining lymph node of a patient with advanced breast cancer by means of ELIspot (Figure 1B; recognition of native survivin95-104: ELTLGEFLKL). It was noted that survivin specific T cells derived from these patients could not be maintained in vitro for prolonged periods of times, unlike almost all other T cell clones we obtained in the past. One could argue that such survivin specific T cells may have become senescent due to continuous in vivo stimulation by tumor cells present in these patient, resulting in shortening of the telomeric ends of the chromosomes and subsequent clonal exhaustion. Due to low T cell numbers we could not determine the length of the telomeric ends of the chromosomes in these T cells.
This argument of telomere erosion, however, surely does not hold for survivin specific T cells induced from PBMC taken from healthy donor blood (results shown in Figures 4, 5 and 6). Prior to in vitro stimulation, these T cells were antigen inexperienced, naive, and therefore will have had long telomeres. The results shown in Figure 6 suggest that survivin specific T cells can only be maintained when the percentage remains below a certain level, which may vary per donor or activation status of the T cells. Another example of this is shown in Figure 5, where we found survivin specific T cells up to 10% of the cells in the life gate of the FACS. However, when these cells were enriched and activated via feeder mix, the percentage of survivin specific T cells dropped dramatically.
A number of research groups have documented the existence of survivin specific T cells, in mice as well as in man. Sorensen et al. published on the generation of an HLA-A2 restricted, survivin(96–104) specific T cell clone . This T cell clone, derived from a breast cancer patient, was able to kill peptide loaded T2-target cells in an HLA-A2 restricted fashion. Moreover the T cell clone was able to recognize and kill a series of HLA-A2 positive tumors cells in classical cytotoxicity assays. In contrast to this, Leisegang et al. reported on the lack of success in generating survivin specific T cell lines or clones employing RNA loaded dendritic cells from HLA-A2 positive donors.
Under normal physiologic conditions survivin is a short lived protein . Endogenous expression of survivin, detected by immunohistochemistry and/or western blot analysis, has been documented in human T cells derived from patients with Multiple Sclerosis or Crohn’s disease [55, 56]. Leisegang reported on high level expression of survivin mRNA in activated T cells. Here we have documented the presence of survivin protein in activated CD8+ T cells, and absence thereof in resting T cells (results shown in Figure 7). Since survivin is a protein which is rapidly ubiquitinylated and degraded , it would be reasonable to assume that survivin derived protein fragments are also processed and presented in MHC class I, thus making activated T cells an unintended target for survivin specific T cells.
In a commentary, Aqui and Vonderheide pointed out that endogenous expression of potential tumor antigens, like survivin and telomerase, in activated T cells might lead to fratricide killing of T cells . No signs of fratricide however were reported by Sorensen et al., nor did they report on survivin mRNA or protein expression in T cells. Possible explanations could be that their T cell clone carried a mutation in the epitope of survivin(96–104) thereby losing the ability to be presented, or it may have displayed overall malfunctions in HLA-A2 antigen expression, thereby escaping fratricide killing.
Recently, Leisegang et al. showed that in vitro cultured, T cell receptor transgenic, survivin(96–104) specific T cells underwent fratricide in an HLA-A2 dependent manner . They used dendritic cells and T cells from HLA-A2 negative donors. DC were electroporated with mRNA encoding full length survivin in combination with HLA-A2 for the induction of HLA-A2 restricted survivin specific T cells. Resulting, HLA-A2 negative, T cells were capable of killing HLA-A2, survivin double positive tumour cells. Introduction of HLA-A2 restricted, survivin specific T cell receptors into polyclonal HLA-A2 positive T cells led to fratricide killing of neighboring T cells .
In our experiments we noted that survivin specific T cells could not be maintained in culture for prolonged periods of time. Although we were unable to check for fratricide mediated killing of neighboring T cells, due to a lack of sufficient T cell numbers, our findings can very well be explained by the observations made by Leisegang et al. for the immunodominant T cell epitope survivin(96–104). Although speculative, we documented lack of T cell outgrowth for the survivin(5–14) epitope (TLPPAWQPF) shown in Figure 1 as well.
Fratricide amongst survivin specific CD8+ T cells has now been documented . It remains unclear whether fratricide will also occur in CD4+ T cells on the basis of survivin epitopes presented in MHC-class II [59, 60]. A number of different splice variants have been described for survivin [16–19]. Whether all of these are expressed in activated T cells remains to be elucidated. One could envision that T cell reactivity directed against survivin splice variants, expressed in tumor cells but not in T cells, may still be useful in cancer immunotherapy approaches [61, 62]. This notion may be exemplified by the HLA-A24 restricted survivin 2B epitope 80–88 generated by Takahasi and colleagues . The isolation of HNSCC tumor infiltrating T cells and the identification of epitopes being recognized may offer new therapeutic targets. Alternatively, clinical use of ex vivo expanded tumor infiltrating T cells with a range of (unknown) specificities may also provide a viable treatment option for HNSCC patients . Survivin as an immunotherapeutic target may still be useful in DC based active immunotherapy, since in vivo the percentages of survivin specific T cells will most likely remain below the ‘fratricide threshold’. However for adoptive transfer purposes the use of survivin specific T cells is self-destructive and therefore not feasible.
We thank Dr JA Rodriguez for the original survivin wild type construct, Dr. V van Tendeloo for the original pGEM4Z vector, EW Kueter for co-production of tetramers, FL Schneiders and CSE Verbrugge for technical assistance.
This work was supported by grant VU2007-3814 from the Dutch Cancer Society.
- Kamangar F, Dores GM, Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006, 24: 2137-2150. 10.1200/JCO.2005.05.2308.View ArticlePubMedGoogle Scholar
- Moore SR, Johnson NW, Pierce AM, Wilson DF: The epidemiology of mouth cancer: a review of global incidence. Oral Dis. 2000, 6: 65-74.View ArticlePubMedGoogle Scholar
- Whiteside TL: Anti-tumor vaccines in head and neck cancer: targeting immune responses to the tumor. Curr Cancer Drug Targets. 2007, 7: 633-642. 10.2174/156800907782418310.View ArticlePubMedGoogle Scholar
- Schutt C, Bumm K, Mirandola L: Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma. Int Rev Immunol. 2012, 31: 22-42. 10.3109/08830185.2011.637253.PubMed CentralView ArticlePubMedGoogle Scholar
- Turksma AW, Braakhuis BJ, Bloemena E, Meijer CJ, Leemans CR, Hooijberg E: Immunotherapy for head and neck cancer patients: shifting the balance. Immunotherapy. 2013, 5: 49-61. 10.2217/imt.12.135.View ArticlePubMedGoogle Scholar
- Small S, Keerthivasan G, Huang Z, Gurbuxani S, Crispino JD: Overexpression of survivin initiates hematologic malignancies in vivo. Leukemia. 2010, 24: 1920-1926. 10.1038/leu.2010.198.PubMed CentralView ArticlePubMedGoogle Scholar
- Fisk B, Blevins TL, Wharton JT, Ioannides CG: Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med. 1995, 181: 2109-2117. 10.1084/jem.181.6.2109.View ArticlePubMedGoogle Scholar
- Schmitz M, Diestelkoetter P, Weigle B: Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res. 2000, 60: 4845-4849.PubMedGoogle Scholar
- Kawashima I, Hudson SJ, Tsai V: The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol. 1998, 59: 1-14.View ArticlePubMedGoogle Scholar
- Chikamatsu K, Albers A, Stanson J: P53(110–124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. Cancer Res. 2003, 63: 3675-3681.PubMedGoogle Scholar
- Li F, Ambrosini G, Chu EY: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998, 396: 580-584. 10.1038/25141.View ArticlePubMedGoogle Scholar
- Altieri DC: The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol. 2006, 18: 609-615. 10.1016/j.ceb.2006.08.015.View ArticlePubMedGoogle Scholar
- Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997, 3: 917-921. 10.1038/nm0897-917.View ArticlePubMedGoogle Scholar
- Andersen MH, Svane IM, Becker JC, Straten PT: The universal character of the tumor-associated antigen survivin. Clin Cancer Res. 2007, 13: 5991-5994. 10.1158/1078-0432.CCR-07-0686.View ArticlePubMedGoogle Scholar
- Su L, Wang Y, Xiao M, Lin Y, Yu L: Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010, 110: 484-491. 10.1016/j.tripleo.2010.04.009.View ArticlePubMedGoogle Scholar
- Wang HW, Sharp TV, Koumi A, Koentges G, Boshoff C: Characterization of an anti-apoptotic glycoprotein encoded by Kaposi’s sarcoma-associated herpesvirus which resembles a spliced variant of human survivin. EMBO J. 2002, 21: 2602-2615. 10.1093/emboj/21.11.2602.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhu N, Gu L, Findley HW, Li F, Zhou M: An alternatively spliced survivin variant is positively regulated by p53 and sensitizes leukemia cells to chemotherapy. Oncogene. 2004, 23: 7545-7551. 10.1038/sj.onc.1208038.View ArticlePubMedGoogle Scholar
- Ling X, Cheng Q, Black JD, Li F: Forced expression of survivin-2B abrogates mitotic cells and induces mitochondria-dependent apoptosis by blockade of tubulin polymerization and modulation of Bcl-2, Bax, and survivin. J Biol Chem. 2007, 282: 27204-27214. 10.1074/jbc.M705161200.PubMed CentralView ArticlePubMedGoogle Scholar
- Caldas H, Honsey LE, Altura RA: Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer. 2005, 4: 11-10.1186/1476-4598-4-11.PubMed CentralView ArticlePubMedGoogle Scholar
- Qi G, Kudo Y, Ando T: Nuclear Survivin expression is correlated with malignant behaviors of head and neck cancer together with Aurora-B. Oral Oncol. 2010, 46: 263-270. 10.1016/j.oraloncology.2010.01.004.View ArticlePubMedGoogle Scholar
- Kitamura H, Torigoe T, Hirohashi Y: Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma. Virchows Arch. 2013, 462: 101-107. 10.1007/s00428-012-1343-7.View ArticlePubMedGoogle Scholar
- Karanikas V, Soukou F, Kalala F: Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals. Clin Immunol. 2008, 129: 230-240. 10.1016/j.clim.2008.07.024.View ArticlePubMedGoogle Scholar
- Andersen MH, Pedersen LO, Becker JC, Straten PT: Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 2001, 61: 869-872.PubMedGoogle Scholar
- Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, Straten PT: Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001, 61: 5964-5968.PubMedGoogle Scholar
- Reker S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, Andersen MH: HLA-B35-restricted immune responses against survivin in cancer patients. Int J Cancer. 2004, 108: 937-941. 10.1002/ijc.11634.View ArticlePubMedGoogle Scholar
- Casati C, Dalerba P, Rivoltini L: The apoptosis inhibitor protein survivin induces tumor-specific CD8+ and CD4+ T cells in colorectal cancer patients. Cancer Res. 2003, 63: 4507-4515.PubMedGoogle Scholar
- Siegel S, Steinmann J, Schmitz N, Stuhlmann R, Dreger P, Zeis M: Identification of a survivin-derived peptide that induces HLA-A*0201-restricted antileukemia cytotoxic T lymphocytes. Leukemia. 2004, 18: 2046-2047. 10.1038/sj.leu.2403510.View ArticlePubMedGoogle Scholar
- Filipazzi P, Pilla L, Mariani L: Limited induction of tumor cross-reactive T cells without a measurable clinical benefit in early melanoma patients vaccinated with human leukocyte antigen class I-modified peptides. Clin Cancer Res. 2012, 18: 6485-6496. 10.1158/1078-0432.CCR-12-1516.View ArticlePubMedGoogle Scholar
- Weide B, Zelba H, Derhovanessian E: Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis. J Clin Oncol. 2012, 30: 1835-1841. 10.1200/JCO.2011.40.2271.View ArticlePubMedGoogle Scholar
- Zeis M, Siegel S, Wagner A: Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol. 2003, 170: 5391-5397.View ArticlePubMedGoogle Scholar
- Siegel S, Wagner A, Schmitz N, Zeis M: Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model. Br J Haematol. 2003, 122: 911-914. 10.1046/j.1365-2141.2003.04535.x.View ArticlePubMedGoogle Scholar
- Xiang R, Mizutani N, Luo Y: A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res. 2005, 65: 553-561.PubMedGoogle Scholar
- Nagaraj S, Pisarev V, Kinarsky L: Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. J Immunother. 2007, 30: 169-179. 10.1097/01.cji.0000211329.83890.ba.View ArticlePubMedGoogle Scholar
- Rapoport AP, Aqui NA, Stadtmauer EA: Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood. 2011, 117: 788-797. 10.1182/blood-2010-08-299396.PubMed CentralView ArticlePubMedGoogle Scholar
- Miyazaki A, Kobayashi J, Torigoe T: Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer. Cancer Sci. 2011, 102: 324-329. 10.1111/j.1349-7006.2010.01789.x.View ArticlePubMedGoogle Scholar
- Becker JC, Andersen MH, Hofmeister-Muller V: Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol Immunother. 2012, 61: 2091-2103. 10.1007/s00262-012-1266-9.PubMed CentralView ArticlePubMedGoogle Scholar
- Ellebaek E, Engell-Noerregaard L, Iversen TZ: Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunol Immunother. 2012, 61: 1791-1804. 10.1007/s00262-012-1242-4.View ArticlePubMedGoogle Scholar
- Bontkes HJ, Kramer D, Ruizendaal JJ: Dendritic cells transfected with interleukin-12 and tumor-associated antigen messenger RNA induce high avidity cytotoxic T cells. Gene Ther. 2007, 14: 366-375. 10.1038/sj.gt.3302874.View ArticlePubMedGoogle Scholar
- Bontkes HJ, Ruizendaal JJ, Kramer D: Constitutively active STAT5b induces cytokine-independent growth of the acute myeloid leukemia-derived MUTZ-3 cell line and accelerates its differentiation into mature dendritic cells. J Immunother. 2006, 29: 188-200. 10.1097/01.cji.0000197095.00359.67.View ArticlePubMedGoogle Scholar
- Van Driessche A, Ponsaerts P, Van Bockstaele DR, Van Tendeloo VF, Berneman ZN: Messenger RNA electroporation: an efficient tool in immunotherapy and stem cell research. Folia Histochem Cytobiol. 2005, 43: 213-216.PubMedGoogle Scholar
- Schreurs MW, Scholten KB, Kueter EW, Ruizendaal JJ, Meijer CJ, Hooijberg E: In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones. J Immunol. 2003, 171: 2912-2921.View ArticlePubMedGoogle Scholar
- Herr W, Schneider J, Lohse AW, Meyer zum Buschenfelde KH, Wolfel T: Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J Immunol Methods. 1996, 191: 131-142. 10.1016/0022-1759(96)00007-5.View ArticlePubMedGoogle Scholar
- Verra NC, Jorritsma A, Weijer K: Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice. Cancer Res. 2004, 64: 2153-2161. 10.1158/0008-5472.CAN-03-1339.View ArticlePubMedGoogle Scholar
- Hooijberg E, Ruizendaal JJ, Snijders PJ, Kueter EW, Walboomers JM, Spits H: Immortalization of human CD8+ T cell clones by ectopic expression of telomerase reverse transcriptase. J Immunol. 2000, 165: 4239-4245.View ArticlePubMedGoogle Scholar
- Turksma AW, Bontkes HJ, Ruizendaal JJ: Increased cytotoxic capacity of tumor antigen specific human T cells after in vitro stimulation with IL21 producing dendritic cells. Hum Immunol. 2013, 74 (5): 506-513. 10.1016/j.humimm.2013.01.014.View ArticlePubMedGoogle Scholar
- Bontkes HJ, Kramer D, Ruizendaal JJ, Meijer CJ, Hooijberg E: Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells. Clin Immunol. 2008, 127: 375-384. 10.1016/j.clim.2008.02.001.View ArticlePubMedGoogle Scholar
- Heemskerk MH, Hooijberg E, Ruizendaal JJ: Enrichment of an antigen-specific T cell response by retrovirally transduced human dendritic cells. Cell Immunol. 1999, 195: 10-17. 10.1006/cimm.1999.1520.View ArticlePubMedGoogle Scholar
- Hooijberg E, Bakker AQ, Ruizendaal JJ, Spits H: NFAT-controlled expression of GFP permits visualization and isolation of antigen-stimulated primary human T cells. Blood. 2000, 96: 459-466.PubMedGoogle Scholar
- Santegoets SJ, Schreurs MW, Reurs AW: Identification and characterization of ErbB-3-binding protein-1 as a target for immunotherapy. J Immunol. 2007, 179: 2005-2012.View ArticlePubMedGoogle Scholar
- Santegoets SJ, Schreurs MW, Masterson AJ: In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line. Cancer Immunol Immunother. 2006, 55: 1480-1490. 10.1007/s00262-006-0142-x.View ArticlePubMedGoogle Scholar
- Schreurs MW, Kueter EW, Scholten KB, Lemonnier FA, Meijer CJ, Hooijberg E: A single amino acid substitution improves the in vivo immunogenicity of the HPV16 oncoprotein E7(11–20) cytotoxic T lymphocyte epitope. Vaccine. 2005, 23: 4005-4010. 10.1016/j.vaccine.2005.03.014.View ArticlePubMedGoogle Scholar
- Schreurs MW, Kueter EW, Scholten KB, Kramer D, Meijer CJ, Hooijberg E: Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope. Cancer Immunol Immunother. 2005, 54: 703-712. 10.1007/s00262-004-0611-z.View ArticlePubMedGoogle Scholar
- Sorensen RB, Svane IM, Straten PT, Andersen MH: A survivin specific T-cell clone from a breast cancer patient display universal tumor cell lysis. Cancer Biol Ther. 2008, 7: 1885-1887. 10.4161/cbt.7.12.6935.View ArticlePubMedGoogle Scholar
- Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR: The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci. 2000, 113 (Pt 23): 4363-4371.PubMedGoogle Scholar
- Sharief MK, Semra YK: Heightened expression of survivin in activated T lymphocytes from patients with multiple sclerosis. J Neuroimmunol. 2001, 119: 358-364. 10.1016/S0165-5728(01)00389-7.View ArticlePubMedGoogle Scholar
- de Souza HS, West GA, Rebert N, de la MC, Drazba J, Fiocchi C: Increased levels of survivin, via association with heat shock protein 90, in mucosal T cells from patients with Crohn’s disease. Gastroenterology. 2012, 143: 1017-1026. 10.1053/j.gastro.2012.06.039.PubMed CentralView ArticlePubMedGoogle Scholar
- Aqui NA, Vonderheide RH: Survivin as a universal tumor antigen for novel cancer immunotherapy: functions of a killer clone. Cancer Biol Ther. 2008, 7: 1888-1889. 10.4161/cbt.7.12.7219.View ArticlePubMedGoogle Scholar
- Leisegang M, Wilde S, Spranger S: MHC-restricted fratricide of human lymphocytes expressing survivin-specific transgenic T cell receptors. J Clin Invest. 2010, 120: 3869-3877. 10.1172/JCI43437.PubMed CentralView ArticlePubMedGoogle Scholar
- Tanaka M, Butler MO, Ansen S: Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell. Clin Cancer Res. 2011, 17: 5392-5401. 10.1158/1078-0432.CCR-10-3083.PubMed CentralView ArticlePubMedGoogle Scholar
- Widenmeyer M, Griesemann H, Stevanovic S: Promiscuous survivin peptide induces robust CD4(+) T-cell responses in the majority of vaccinated cancer patients. Int J Cancer. 2012, 131: 140-149. 10.1002/ijc.26365.View ArticlePubMedGoogle Scholar
- Kameshima H, Tsuruma T, Kutomi G: Immunotherapeutic benefit of alpha-interferon (IFNalpha) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients. Cancer Sci. 2013, 104: 124-129. 10.1111/cas.12046.View ArticlePubMedGoogle Scholar
- Kameshima H, Tsuruma T, Torigoe T: Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients. Cancer Sci. 2011, 102: 1181-1187. 10.1111/j.1349-7006.2011.01918.x.View ArticlePubMedGoogle Scholar
- Takahashi A, Torigoe T, Tamura Y: Heat shock enhances the expression of cytotoxic granule proteins and augments the activities of tumor-associated antigen-specific cytotoxic T lymphocytes. Cell Stress Chaperones. 2012, 17: 757-763. 10.1007/s12192-012-0348-0.PubMed CentralView ArticlePubMedGoogle Scholar
- Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C: White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res. 2011, 17: 1664-1673. 10.1158/1078-0432.CCR-10-2272.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.